Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

<p>Supplementary Figure S4.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Laura Boucai (15054310) (author)
Kolejni autorzy:	Mahesh Saqcena (15054313) (author), Fengshen Kuo (14947443) (author), Ravinder K. Grewal (15054316) (author), Nicholas Socci (15054319) (author), Jeffrey A. Knauf (15008595) (author), Gnana P. Krishnamoorthy (15054322) (author), Mabel Ryder (15054325) (author), Alan L. Ho (15054328) (author), Ronald A. Ghossein (15054331) (author), Luc G.T. Morris (14956461) (author), Venkatraman Seshan (15054334) (author), James A. Fagin (15054337) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Endocrine-Related Cancers Precision Medicine
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
od: Laura Boucai (15054310)
Wydane: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
od: Athanasios Bikas (16006076)
Wydane: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Wydane: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Wydane: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
od: Yansong Lin (16374208)
Wydane: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
od: Anna Eriksson (15352461)
Wydane: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
od: Anna Eriksson (15352461)
Wydane: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
od: Katleen Janssens (15053356)
Wydane: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
od: Iris van 't Erve (15054503)
Wydane: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_on1sk2nssdss0j7bm6688ebkms